ACHE and Alzheimer disease: However, the successful launch of lecanemab and aducanumab marks the entry of anti-Aβ monoclonal antibodies into the mainstream drug queue for the treatment of AD, following acetylcholinesterase inhibitors and NMDA receptor antagonists, offering more treatment choices for patients with AD (Yang and Qiu, 2024; Varadharajan et al., 2023).